About
Part 2: RNA fusion detection

Originally presented at ESMO 2022

Clinical validation of novel RNA fusion detection for NSCLC with SOPHiA DDM™ Dx RNAtarget Oncology Solution​
Prof. Alexander Harlé, PhD

Enabling clinical workflows in Trusted Research Environments ​
Gaetano Bonifacio, PhD

Disclaimer notice:
The term SOPHIA used by the speaker refers to SOPHiA GENETICS and its products.
The opinions expressed during this presentation are these of the speaker and may not represent the opinions of SOPHiA GENETICS.
SOPHiA GENETICS does not provide support in the validation of custom products for clinical use.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at support@sophiagenetics.com to obtain the appropriate product information for your country of residence.
Agenda
  • Clinical validation of novel RNA fusion detection for NSCLC with SOPHiA DDM™ Dx RNAtarget Technology
  • Enabling clinical workflows in Trusted Research Environments ​
Presenters
1571226-1556610220
SOPHiA GENETICS
1665087056-e33b55bcf2dd855e
Prof. Alexander Harlé, PhD
Biologist/Professor of liquid biopsy and tumor heterogeneity group, Institut de Cancérologie de Lorraine-Alexis Vautrin ​
1665087299-a53c62ae2c53cab5
Gaetano Bonifacio, PhD
Industry Advisor-Healthcare, Microsoft​
Register To Watch Recording
Full name*
Email Address*
Institution/Company*
City*
Country *
We use BigMarker as our webinar platform. By clicking Register, you acknowledge that the information you provide will be transferred to BigMarker processing in accordance with their Terms of Service and Privacy Policy.